Cubist Pharmaceuticals (NASDAQ: CBST) is a biopharmaceutical company focused on the research, development and commercialization of pharmaceutical products that address unmet medical needs in the acute care environment. The company is headquartered in Lexington, Massachusetts. In the U.S., Cubist markets CUBICIN® (daptomycin for injection), the first IV antibiotic from a class of antiinfectives called lipopeptides. Cubist employs 500 people. The company's total net revenues increased 50% to $294.6 million in 2007 from $194.7 million in 2006.
Founded in 1992, Cubist has maintained its focus on becoming a leader in the discovery, development and commercialization of novel antiinfectives for use in hospitals and other acute care environments.
Cubist completed its initial public offering (IPO) in 1996, and shares are listed on NASDAQ (ticker symbol: CBST). In 1997, at a time when most pharmaceutical companies had abandoned discovery and development of antibiotics, Cubist in-licensed daptomycin, a first-in-class cyclic lipopeptide antibiotic drug candidate, originally discovered by scientists at Eli Lilly, which had discontinued its work on daptomycin as a drug candidate. Based on a breakthrough by Cubist scientists, we resumed human trials with daptomycin in IV form and it was approved by the FDA as CUBICIN (daptomycin for injection) and launched in the U.S. in 2003. CUBICIN has to date experienced the most successful antibiotic launch in U.S. history, on a dollar sales basis. In 2005, Cubist submitted a sNDA seeking an expanded label for CUBICIN based on results of the Company's landmark Phase 3 trial studying the treatment of S.aureus bloodstream infections, including infective endocarditis. Following the positive recommendations of the Anti-infective Drugs Advisory Committee in March 2006, the FDA approved an expanded U.S. label for CUBICIN on May 25, 2006. For information on the expanded label please visit www.cubicin.com.
Click here for more information on Cubist's Pipeline.
Click here for more information on our International Partners for CUBICIN.